Table 1.

Previously reported criteria and amplification rates of Her-2/neu in prostate cancer

First author	Patient numbers	Probe	Criteria for amplification	% Amplified
Ross5	113	Quantum Appligene	≥5 signals in ≥20%	41%
Mark6	86	Vysis	Ratio ≥1.5	9%
Bubendorf12	262 tumour microarrays	Vysis	Ratio ≥3	0%
Oxley	114	Quantum Appligene	≥5 signals in ≥20%	1.75%
			Ratio ≥2	0%